Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature

D. Pastorelli; G. Cartei; F. Zustovich; F. Marchese; G. Artioli; S. Zovato; S. Binato; R. Ceravolo; S. Cingarlini; F. Salmaso; M. Mattiazzi; C. Sanavio; F. Farinati; G. Zanus; U. Cillo

doi:10.1093/annonc/mdj972

Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature

D. Pastorelli, G. Cartei, F. Zustovich, F. Marchese, G. Artioli, S. Zovato, S. Binato, R. Ceravolo, S. Cingarlini, F. Salmaso, M. Mattiazzi, C. Sanavio, F. Farinati, G. Zanus, U. Cillo

Istituto Oncologico Veneto

Research output: Contribution to journal › Article

Abstract

Background: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. Pa tients and methods: Clinical trials for biliary and hepatic carcinoma have been reviewed. Results: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m² d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).

Original language	English
Journal	Annals of Oncology
Volume	17
Issue number	SUPPL. 5
DOIs	https://doi.org/10.1093/annonc/mdj972
Publication status	Published - May 2006

Keywords

Biliary tract cancers
Chemotherapy
Hepatocellular carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/annonc/mdj972

Fingerprint Dive into the research topics of 'Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature'. Together they form a unique fingerprint.

Cite this

Pastorelli, D., Cartei, G., Zustovich, F., Marchese, F., Artioli, G., Zovato, S., Binato, S., Ceravolo, R., Cingarlini, S., Salmaso, F., Mattiazzi, M., Sanavio, C., Farinati, F., Zanus, G., & Cillo, U. (2006). Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature. Annals of Oncology, 17(SUPPL. 5). https://doi.org/10.1093/annonc/mdj972

Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy : Preliminary results and review of the literature. / Pastorelli, D.; Cartei, G.; Zustovich, F.; Marchese, F.; Artioli, G.; Zovato, S.; Binato, S.; Ceravolo, R.; Cingarlini, S.; Salmaso, F.; Mattiazzi, M.; Sanavio, C.; Farinati, F.; Zanus, G.; Cillo, U.

In: Annals of Oncology, Vol. 17, No. SUPPL. 5, 05.2006.

Research output: Contribution to journal › Article

Pastorelli, D, Cartei, G, Zustovich, F, Marchese, F, Artioli, G, Zovato, S, Binato, S, Ceravolo, R, Cingarlini, S, Salmaso, F, Mattiazzi, M, Sanavio, C, Farinati, F, Zanus, G & Cillo, U 2006, 'Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature', Annals of Oncology, vol. 17, no. SUPPL. 5. https://doi.org/10.1093/annonc/mdj972

Pastorelli, D. ; Cartei, G. ; Zustovich, F. ; Marchese, F. ; Artioli, G. ; Zovato, S. ; Binato, S. ; Ceravolo, R. ; Cingarlini, S. ; Salmaso, F. ; Mattiazzi, M. ; Sanavio, C. ; Farinati, F. ; Zanus, G. ; Cillo, U. / Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy : Preliminary results and review of the literature. In: Annals of Oncology. 2006 ; Vol. 17, No. SUPPL. 5.

@article{c825d26ae49540d796f48c93402007df,

title = "Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature",

abstract = "Background: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. Pa tients and methods: Clinical trials for biliary and hepatic carcinoma have been reviewed. Results: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m2 d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).",

keywords = "Biliary tract cancers, Chemotherapy, Hepatocellular carcinoma",

author = "D. Pastorelli and G. Cartei and F. Zustovich and F. Marchese and G. Artioli and S. Zovato and S. Binato and R. Ceravolo and S. Cingarlini and F. Salmaso and M. Mattiazzi and C. Sanavio and F. Farinati and G. Zanus and U. Cillo",

year = "2006",

month = may,

doi = "10.1093/annonc/mdj972",

language = "English",

volume = "17",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "SUPPL. 5",

}

TY - JOUR

T1 - Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy

T2 - Preliminary results and review of the literature

AU - Pastorelli, D.

AU - Cartei, G.

AU - Zustovich, F.

AU - Marchese, F.

AU - Artioli, G.

AU - Zovato, S.

AU - Binato, S.

AU - Ceravolo, R.

AU - Cingarlini, S.

AU - Salmaso, F.

AU - Mattiazzi, M.

AU - Sanavio, C.

AU - Farinati, F.

AU - Zanus, G.

AU - Cillo, U.

PY - 2006/5

Y1 - 2006/5

N2 - Background: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. Pa tients and methods: Clinical trials for biliary and hepatic carcinoma have been reviewed. Results: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m2 d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).

AB - Background: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. Pa tients and methods: Clinical trials for biliary and hepatic carcinoma have been reviewed. Results: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m2 d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).

KW - Biliary tract cancers

KW - Chemotherapy

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33745597366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745597366&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj972

DO - 10.1093/annonc/mdj972

M3 - Article

C2 - 16807446

AN - SCOPUS:33745597366

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -